Transactions

Osmotica Pharmaceuticals plc’s license agreement with Santen Pharmaceuticals Co., Ltd to develop, register and commercialize RVL-1201 in Japan, China, other Asian countries and EMEA countries

Date Announced:
07/28/2020

client:
Osmotica Pharmaceuticals plc

Status:
Closed – 07/28/2020

Value:
$89 million in upfront and milestone payments + tiered royalties